Available online at www.derpharmachemica.com



Scholars Research Library

Der Pharma Chemica, 2011, 3(1): 181-188 (http://derpharmachemica.com/archive.html)



Synthesis and antimicrobial activity evaluation of new dialkyl heteroarylphosphonates

K.Venkata Ramana^a, K. C. Venkata Subbaiah^b, V. Lokanatha^b and C. Naga Raju^a*

^aDepartment of Chemistry, Sri Venkateswara University, Tirupati, India ^bDepartment of Zoology, Sri Venkateswara University, Tirupati, India

ABSTRACT

Synthesis of new dialkyl heteroaryl phosphonates (**4a-f and 5a-f**) is accomplished with high yields via Michaelis-Arbuzov rearrangement by the reaction of various heteroaryl halides with triethyl /triisopropyl phosphite at 50-55 °C in dry tetrahydrofuran (THF) in the presence of $BF_3.Et_2O$ as a catalyst. The structures of the title compounds were established by elemental analysis and spectral data (IR, ¹H, ¹³C and ³¹P NMR and LC- mass) and their antimicrobial activity was evaluated. The title compounds exhibited moderate antimicrobial activity.

Key words: dialkyl heteroaryl phosphonates, triethyl/triisopropyl phosphite, BF₃.Et₂O, Antimicrobial activity, MIC.

INTRODUCTION

Michaelis-Arbuzov reaction is one of the most versatile routes to synthesize phosphonates, phosphinates and phosphine oxides, containing a phosphorus-carbon bond by the reaction of trialkyl phosphite and alkyl halides which are particularly scarce in nature [1-2]. Their diverse biological activity has attracted considerable synthetic and pharmacological interest [3]. Michaelis-Arbuzov Microwave assisted solid surface synthesis accomplishes the phosphonylation of aromatic compounds under catalytical conditions of organophosphorus compounds [4-5]. The catalytic Arbuzov rearrangement involves iodine [6], alkali metal iodide [7] and Ni [II] chloride [8] as catalysts. So far reported synthetic procedures for phosphonates require very high temperature long time and pressure [9]. Renard et al. used BF₃.Et₂O and TMSOTf as Lewis acid catalysts these in the Arbuzov rearrangement of phosphinates to phosphine oxides [10] and found that these catalysts are very effective at 60 $\degree C$ and the yields were 87 and 91 respectively. We herein report the synthesis of new dialkylheteroaryl

5a-f

phosphonates **4a-f** and **5a-f** using BF₃.Et₂O as a Lewis acid catalyst under mild reaction conditions (50-55 °C) with high yields their structures were characterized by elemental analysis, IR, NMR (1 H, 13 C, 31 P NMR) and mass spectral data evaluated their antimicrobial activity

MATERIALS AND METHODS

Experimental Chemistry

Chemicals were purchased from Sigma – Aldrich, Merck and Lancaster, and were used as such without further purification. All solvents used for spectroscopic and other physical studies were reagent grade and were further purified by literature methods (14). IR spectra were recorded as KBr pellets on a Perkin Elmer 283 unit. ¹H, ¹³C, ³¹P NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer operating at 400 MHz for ¹H, 100 MHz for ¹³C, 161.9 MHz for ³¹P NMR were recorded in DMSO and referenced to TMS (H¹ & ¹³C) and 85% H₃PO₄ (³¹P). LC-MS spectra were recorded on a Joel SX 102 DA/600 Mass spectrometer. Elemental analyses were performed on a Thermo Finnigan Instrument at University of Hyderabad, Hyderabad, India.

RESULTS AND DISCUSSION

The heteroaryl phosphonates (**4a-f/5a-f**) were synthesized by using BF₃.Et₂O as a catalyst within 4-6 hrs with high yields (69-78%) through Michaelies-Arbuzov rearrangement. The chemical structures of all the title compounds (**4a-f/5a-f**) were characterized by IR, ¹H, ¹³C, ³¹P NMR and mass spectral data. The characteristic IR stretching absorptions were observed in the regions 1224-1256 (P=O), 1081-1012 (P-O-Caliphatic), 1420-1470 (P-Caromaic).In ¹H NMR, the methyleneoxy protons appeared as multiplets at δ 4.21 - 4.01 [13].

$$R-X + P(OR^{1})_{3} \xrightarrow{BF_{3}.Et_{2}O} R \xrightarrow{H} P \xrightarrow{O} OR^{1}$$

$$2a-f R^{1} = Et$$

$$1 a-f 3a-f R^{1} = i-Pr \qquad 4a-f$$

CompoundRCompoundR4a, 5a
$$\checkmark$$
 \checkmark \checkmark \land 4b, 5b \bigcirc \bigcirc \checkmark \bigvee \bigvee 4b, 5b \bigcirc \bigcirc \checkmark \checkmark \bigvee 4c, 5c \bigcirc \bigvee \bigvee \bigvee \bigvee Scheme 1 \checkmark \bigcirc \bigcirc \bigcirc

The methineoxy protons appeared as two distinct doublets in the region of δ 4.58 - 4.76 (d, J = 6.2-6.6 Hz). In ¹³C NMR, methyleneoxy carbons resonated as a doublet at δ 62.3 - 61.4 (d, J = 5.4-5.8 Hz) [13]. ³¹P NMR chemical shifts were observed in the region -11.2 to 9.32 ppm [13].

www.scholarsresearchlibrary.com

C. Naga Raju et al

The antibacterial activity of the title compounds **4a** and **5a** showed pronounced activity against both G^{+ve} and G^{-ve} microorganisms, and **4b** and **5b** exhibit good activity against G^{-ve} organisms only. This mode of action might be due to change of side chain at P of the title compounds. In addition to this remaining title compounds showed moderate to high antimicrobial activity.

Pharmacology

Antimicrobial activity

The antimicrobial activity of the title compounds was evaluated by the standard methods and the results were presented in the results and discussion section.

Antibacterial activity

The antibacterial activity of the title compounds was evaluated by Mueller-Hinton agar disc diffusion method [11, 12] against Gram positive bacteria *Bacillus subtilis* and *Enterococcus faecalis* and Gram negative bacteria *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. The bacterial suspension was prepared with 1.3×10^9 cells/mL concentrations approximately for the bioassay. The activity was measured at two different concentrations for all the title compounds at $25 \,\mu$ g/mL and $50 \,\mu$ g/mL. Then the title compounds were introduced on to the disc. Thus the disc was completely saturated with the test compound. Then the disc was introduced on to the upper layer of the medium with the bacteria. The bio-activity of compounds was determined by measuring diameter of the inhibition zone (**DIZ**) in millimeters and minimum inhibitory concentration (**MIC**) in mg/ mL by taking Ampicillin as standard reference in order to control the sensitivity of the bacteria. Each test was done in triplicate and the average values were taken as a final result.

	Diameter of Inhibition Zone in (mm)							
Compound	Bacillus subtilis		Enterococcus faecalis		Klebsiella pneumoniae		Pseudomonas aeruginosa	
-	25	50	25	50	25	50	25	50
4 a	4.1	11.4	3.8	10.7	4.4	12.3	3.6	13.7
4b	5.3	14.1	4.8	14.6	3.3	8.9	3.7	11.3
4 c	3.7	8.1	1.5	5.0	2.2	5.2	3.4	7.9
4d	1.8	4.3	1.5	3.9	2.4	7.6	2.6	7.1
4e	1.5	3.7	1.5	2.8	1.7	5.4	1.8	5.2
4f	1.3	2.9	1.4	2.5	1.6	4.0	1.8	4.6
5a	3.9	13.6	2.5	7.8	5.7	14.2	3.7	11.3
5b	3.2	9.4	3.5	9.0	4.1	10.9	1.7	3.8
5c	2.4	7.5	2.8	7.2	1.9	4.5	1.8	4.2
5d	3.0	5.7	2.7	6.2	3.4	5.9	1.7	3.8
5e	2.4	5.0	2.1	4.4	1.9	4.6	2.7	5.0
5f	2.4	6.7	2.1	6.1	1.3	2.6	1.2	1.5
Ampicillin (20 µg/disc)	21	21	20	20	19	19	18	18

Table 1: Antibacterial activity (DIZ) of the title compounds (4a-f/ 5a-f)

The concentration expressed in $\mu g/disc$ and the diameter of the disc is in mm, solvent DMSO.

Antifungal activity

The antifungal activity of the title compounds was evaluated by agar-well diffusion method using Sabouraud Dextrose Agar. The Petri plates were incubated at 37°C for 24 h for bacteria and 48-72 h at 24°C for fungi. The bio-activity of compounds was determined by measuring

C. Naga Raju et al

diameter of the inhibition zone (**DIZ**) in milli meters. Concentrations of the title compounds were taken as 25 μ g/mL and 50 μ g/mL were evaluated for antifungal activity by using Nystatine as standard reference in order to control the sensitivity of the fungi. Each test was done in triplicate and the average values were taken as a final result.

Evaluation of minimum inhibitory concentration [MIC]

Minimum inhibitory concentration [MIC] was determined for the title compounds. The lowest concentration of antimicrobial compounds that inhibit the visible growth of an organism after overnight incubation period is considered as MIC. The title compounds in concentrations of 1 to 6.3 mg/mL in steps of 100 μ g/mLwere evaluated; 0.1 mL of bacterial inoculums (1.4x10⁶ CFU/mL) was added to each tube. The tubes were incubated aerobically and anerobically at 37 °C for 24 hrs. Two control tubes were maintained for each test, for positive control ampicillin (Hi-media) and negative control nutrient broth having an organism.

	Minimum Inhibitory Concentration (mg/ mL)						
Compound ^a	Bacillus subtilis	Enterococcus faecalis	Klebsiella pneumoniae	Pseudomonas aeruginosa			
4 a	2.6	3.1	3.5	3.8			
4b	3.1	2.9	2.4	3.5			
4 c	4.2	4.6	4.8	4.0			
4d	3.9	4.2	4.7	5.1			
4 e	3.8	5.4	4.8	4.2			
4f	4.2	4.6	4.8	4.0			
5a	3.4	3.8	4.5	4.7			
5b	3.3	3.8	4.2	3.9			
5c	3.3	3.7	3.9	4.5			
5d	4.1	4.4	5.2	5.5			
5e	3.6	3.9	4.7	5.1			
5f	3.4	4.0	4.4	4.9			
Ampicillin (20 μg/disc)	0.1	0.2	0.2	0.3			

Table 2: Antibacterial activity (MIC) of the title compounds $(\mbox{4a-f}/\mbox{ 5a-f})$

^a Solvent DMSO.

Preparation of diethyl/ diisoproyl hetero aryl phosphonates (4a-f & 5a-f)

A mixture of heteroaryl halide (1a-f) (0.002 mole), triethyl phosphite / triisopropyl phosphite (2a-f/ 3a-f) (0.002 mole), BF₃.Et₂O (catalytic amount) were placed in a 50 mL round-bottomed flask in THF (20 mL) and the mixture was stirred at 50-55°C for 4-6 h (Scheme 1) to obtain the products (4a-f/ 5a-f). The reaction progress was monitored by TLC (ethyl acetate and n-Hexane, 7:3). The solvent was removed in a rotaevaporator. The product was purified by column chromatography on silica gel using petroleum ether –ethyl acetate (4:1) as eluent.

Synthesis of diethyl 1*H*-indol-5-yl-phosphonate (4a):

Yield: 76%; Semi solid; IR (KBr): 1224 (P=O), 1065 (P-O-C_{aliphatic}), 1424 (P-C_{Aromatic}), cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.33 (t, 6H, J = 7.6 Hz, CH₂-<u>CH₃</u>), 3.94-4.03 (m, 4H -O<u>CH₂-CH₃</u>), 6.84-7.01 (m, 2H), 7.21 (d, 1H, J = 8.6 Hz, H-2), 7.32 (d, 1H, J = 7.6 Hz, H-3), 8.24 (s,1H, H-4), 7.42 (d, 1H, J = 6.6 Hz, H-6), 10.14 (s, 1H, -NH); ¹³C-NMR (DMSO- d_6) δ : 140.6, 126.6, 124.7, 123.4, 121.2, 120.4, 113.2, 104.6, 61.0, 16.8; ³¹P-NMR (DMSO- d_6) δ : 2.3; LCMS

(m/z): 253 ($M^{+\bullet}$, 100), 224 (72), 208 (46), 163 (35); Anal. Calcd (%) for $C_{12}H_{16}NO_3P$: C, 56.92; H, 6.37; N, 5.53; Found: C, 56.85; H, 6.33; N, 5.58.

	Inhibition zone in (mm)						
Compound	Canc	lida albicans	Aspergillus niger				
	25	50	25	50			
4 a	4.8	15.6	4.6	15.2			
4b	4.3	16.8	4.6	15.5			
4c	3.7	10.1	3.5	8.8			
4d	2.8	6.1	2.0	4.9			
4 e	2.3	6.5	2.0	5.3			
4 f	2.3	4.7	2.5	4.2			
5a	3.9	14.4	5.2	14.5			
5b	1.6	3.9	1.4	5.9			
5c	3.5	8.7	2.9	7.3			
5d	2.4	5.1	2.7	5.6			
5e	3.1	8.3	1.9	3.7			
5f	1.5	4.8	1.5	4.2			
Nystatine	10	10	20	20			
(30 µg/disc)	17	17	20	20			

Table 3: Antifungal activity of the title compounds (4a-f/ 5a-f)

^{*a*} The concentration expressed in $\mu g/disc$ solvent-DMSO.

Synthesis of diisopropyl-1*H*-indol-5-yl-phosphonate (5a):

IR (KBr): 1210 (P=O), 1077 (P-O-C_{aliphatic}), 1466 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.28 (d, 12H, J = 5.2, CH-<u>CH</u>₃), 4.11-4.16 (m, 2H, -O<u>CH</u>-CH₃), 7.32 (d, 1H, J = 7.6 Hz, H-2), 6.41 (d, 1H, J = 6.6 Hz, H-3), 7.48 (d, 1H, J = 8.6 Hz, H-4), 7.12 (d, 1H, J = 7.6 Hz, H-6), 8.24 (s, 1H, H-7), 10.22 (s, 1H, -NH); ¹³C-NMR (DMSO- d_6) δ : 144.6, 128.6, 127.6, 124.2, 122.8, 121.5, 119.2, 104.6, 71.6, 19.8; ³¹P-NMR (DMSO- d_6) δ : -2.65; LCMS (m/z): 281(M⁺⁺, 100), 238 (24), 224 (72), 161 (52), 116 (36); Anal. Calcd (%) for C₁₄H₂₀NO₃P: C, 59.78; H, 7.17; N, 4.98; Found: C, 59.88; H, 7.15; N, 4.91.

Synthesis of diethyl 5-chlorothiophen-2-yl-phosphonate (4b):

Yield: 68%, Semi solid; IR (KBr): 1214 (P=O) , 1052 (P-O-C_{aliphatic}), 1434 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.32 (t, 6H, J = 6.6 Hz, CH₂-<u>CH₃</u>), 4.16-4.22 (m, 4H -O<u>CH₂-CH₃</u>), 7.18 (d, 1H, J = 7.4Hz, H-3), 7.32 (d, 1H, J = 7.6 Hz, H-4); ¹³C-NMR (DMSO- d_6) δ : 132.8, 128.2, 126.4, 122.6, 62.1, 16.4; ³¹P-NMR (DMSO- d_6) δ : 3.5; LCMS (m/z): 254 (M⁺⁺, 100), 225 (65) ,209 (42), 164 (31); Anal. Calcd (%) for C₈H₁₂ClO₃PS: C, 37.73; H, 4.75; Found: C, 37.65; H, 4.75.

Synthesis of diisopropyl-5-chlorothiophen-2-yl-phosphonate (5b):

Yield: 69 %, Semi solid; IR (KBr): 1238 (P=O) , 1062 (P-O-C_{aliphatic}), 1448 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.58 (d, 12H, J = 5.4 Hz, CH-<u>CH</u>₃), 4.82-4.68 (m, 2H, -O<u>CH</u>-CH₃), 7.32 (d, 1H, J = 7.8, H-3), 7.51 (d, 1H, J = 7.8 Hz, H-4); ¹³C-NMR (DMSO- d_6) δ : 128.2, 127.4, 126.8, 125.2, 72.4, 19.4; ³¹P-NMR (DMSO- d_6) δ : -10.2; LCMS (m/z): 282 (M^{+•}, 100), 225 (45), 209 (34),164 (72), 117 (56); Anal.Calcd (%) for C₁₀H₁₆ClO₃PS: C, 42.48; H, 5.70; Found: C, 42.35; H, 5.73 .

Synthesis of diethyl 3-nitropyridin-2-yl-phosphonate (4c):

Yield: 78%, Semi solid; IR (KBr): 1236 (P=O) , 1068 (P-O-C_{aliphatic}), 1424 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.32 (t, 6H, J = 6.42 Hz, CH₂-<u>CH₃</u>), 4.62–4.54 (m, 4H, -O<u>CH₂-CH₃</u>), 7.52-7.71 (m, 3H, H-4, H-5&H-6); ¹³C-NMR (DMSO- d_6): 156.2, 148.4, 147.6, 132.8, 124.62, 62.24, 18.2; ³¹P-NMR (DMSO- d_6) δ : 6.11; LCMS (m/z): 260 (M⁺⁺, 100), 231 (37), 215 (52),170 (64),124 (21); Anal. Calcd (%) for C₉H₁₃N₂O₅P: C, 41.55; H, 5.04; N, 10.77; Found: C, 41.52; H, 5.02; N, 10.72.

Synthesis of diisopropyl-5-chlorothiophen-2-yl-phosphonate (5c):

Yield: 69 %, Semi solid; IR (KBr): 1238 (P=O) , 1032 (P-O-C_{aliphatic}), 1454(P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.42 (d, 12H, J = 4.2 Hz, CH-<u>CH</u>₃), 4.82-4.68 (m, 2H, -O<u>CH</u>-CH₃), 7.32 (d, 1H, J = 7.8, H-3), 7.51 (d, 1H, J = 7.8 Hz, H-4). ¹³C-NMR (DMSO- d_6) δ : 128.2, 127.4, 126.8, 125.2, 72.4, 19.4; ³¹P-NMR (DMSO- d_6) δ : 6.11; LCMS (m/z): 282 (M⁺⁺, 100), 239 (35),161 (67),117 (48); Anal.Calcd (%) for C₁₀H₁₆ClO₃PS: C, 42.48; H, 5.70; Found: C, 42.44; H, 5.68.

Synthesis of diethyl 4,6-dichloropyrimidin-2-yl-phosphonate (4d):

Yield: 78%, Semi solid; IR (KBr): 1243 (P=O) , 1066 (P-O-C_{aliphatic}), 1458 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.36 (t, 6H, J = 6.3 Hz, CH₂-<u>CH₃</u>), 4.48 – 4.52 (m, 4H – O<u>CH₂</u>-CH₃), 8.34 (s, 1H, H-5); ¹³C-NMR (DMSO- d_6) δ : 166.4, 165.8, 161.6, 128.2, 61.2, 19.2; ³¹P-NMR (DMSO- d_6) δ : -1.76; LCMS (m/z): 285 (M⁺⁺, 100), 256 (36), 240 (47), 185 (67),148 (23);Anal. Calcd (%) for C₈H₁₁Cl₂N2O₃P: C, 33.71; H, 3.89; N, 9.83; Found: C, 33.68; H, 3.84; N, 9.80.

Synthesis of diisopropyl-4,6-dichloropyrimidin-2-yl-phosphonate (5d):

Yield: 70 %, Semi solid; IR (KBr): 1252 (P=O) , 1052 (P-O-C_{aliphatic}), 1472 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.48 (d, 12H, J = 4.6 Hz, CH-<u>CH</u>₃), 4.65- 472 (m, 2H, -O<u>CH</u>-CH₃) 9.32 (s, 1H, H-5); ¹³C-NMR (DMSO- d_6) δ : 166.3, 162.4, 160.2, 126.4, 65.6, 19.6; ³¹P-NMR (DMSO- d_6) δ : -2.0; LCMS (m/z): 313 (M⁺⁺, 100), 260 (56), 193(68), 148 (36); Anal. Calcd(%) for C₁₀H₁₅Cl₂N₂O₃P: C, 38.36; H, 4.83; N, 8.95; Found: C, 38.32; H, 4.78; N, 8.90.

Synthesis of diethyl 6-chloropyridazin-3-yl-phosphonate (4e):

Yield: 73%, Semi solid; IR (KBr): 1223 (P=O) , 1062 (P-O-C_{aliphatic}), 1438 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.34 (t, 6H, J = 5.3 Hz, CH₂-<u>CH₃</u>), 4.32-4.46 (m, 4H, -O<u>CH₂-CH₃</u>), 8.12 (d, 1H, J = 6.2Hz, H-4), 7.78 (d, 1H, J = 5.4Hz, H-5); ¹³C-NMR (DMSO- d_6) δ : 160.8, 152.8, 134.6, 126.4, 62.8, 19.7; ³¹P-NMR (DMSO- d_6) δ : 9.3; LCMS (m/z): 250 (M⁺⁺, 100), 225 (45), 209 (26), 164 (63), 115 (21); Anal. Calcd (%) for C₈H₁₂ClN₂O₃P: C, 38.34; H, 4.83; N, 11.18; Found: C, 38.31; H, 4.78; N, 11.12.

Synthesis of diisopropyl-6-chloropyridazin-3-yl-phosphonate (5e):

Yield: 71%, Semi solid; IR (KBr): 1232 (P=O) , 1066 (P-O-C_{aliphatic}), 1474 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.52 (d, 12H, J = 4.8 Hz, CH-<u>CH</u>₃), 4.54 - 4.62 (m, 2H -O<u>CH</u>-CH₃), 7.62 (d, 1H, J = 5.6 Hz, H-4) , 7.89 (d, 1H, J= 6.2Hz, H-5); ¹³C-NMR (DMSO- d_6) δ : 162.6,158.4,152.1,132,4, 68.4, 19.6; ³¹P-NMR (DMSO- d_6) δ : 9.1; LCMS (m/z): 278 (M⁺⁺, 100), 241(65),158 (67), 113 (27); Anal. Calcd (%) for C₈H₁₂ClN₂O₃P: C, 43.10; H, 5.79; N, 10.05; Found: C, 43.06; H, 5.76; N, 10.02.

Synthesis of diethyl-6-chloropyridin-2-yl-phosphonate (4f):

Yield: 78%, Semi solid; IR (KBr): 1228 (P=O) , 1046 (P-O-C_{aliphatic}), 1462 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.32 (t, 6H, J = 6.82 Hz, CH₂-<u>CH₃</u>), 4.34 - 4.42 (m, 4H - O<u>CH₂-CH₃</u>), 8.12 - 8.24 (m, 3H, H-3, H-4 & H-5); ¹³C-NMR (DMSO- d_6) δ : 154.6, 152.8, 148.2, 140.4, 126.8, 61.2, 16.8; ³¹P-NMR (DMSO- d_6) δ : 5.11; LCMS (m/z): 249 (M⁺⁺, 100), 220 (38), 204 (56), 159 (67), 112 (25); Anal. Calcd (%) for C₉H₁₃ClNO₃P: C, 43.26; H, 5.22; N, 5.61; Found: C, 43.21; H, 5.18; N, 5.56.

Synthesis of diisopropyl-6-chloropyridin-2-yl-phosphonate (5f):

Yield: 72%, Semi solid; IR (KBr): 1244 (P=O) , 1048 (P-O-C_{aliphatic}), 1472 (P-C_{Aromatic}) cm⁻¹; ¹H-NMR (400 MHz, DMSO- d_6) δ : 1.38 (d, 12H, J = 4.2 Hz, CH-<u>CH</u>₃),), 4.62-4.72 (m, 2H, -O<u>CH</u>-CH₃), 8.28 - 8.36 (m, 3H, H-3, H-4 & H-5); (¹³C-NMR) (DMSO- d_6) δ : 154.4, 148.4, 141.4, 134.6, 128.2 72.8, 19.8; ³¹P-NMR (DMSO- d_6) δ : -11.21. LCMS (m/z): 277 (M^{+•}, 100), 234 (46), 157 (58), 136 (38), 112 (26); Anal. Calcd (%) for C₁₁H₁₇ClNO₃P: C, 47.58; H, 6.17; N, 5.04; Found: C, 47.54; H, 6.12; N, 4.98.

CONCLUSION

In conclusion, the synthesis of the novel dialkyl heteroaryl phosphonates with high yieds is accomplished in high yields by one-pot two-coponent reaction between heteroaryl halides and trialkyl phosphites in the presence of BF₃.Et₂O as a catalyst in THF at 50-55 °C Their structures were established by elemental analysis, IR, NMR (¹H, ¹³Cand ³¹P) and LC mas spectra. All the title compounds exhibited moderate antimicrobial activity. Their minimum inhibition concentrations were also evaluated.

Acknowledgement

The authors express their grateful thanks to UGC, New Delhi for sanctioning a major research project (F.No. 34-356/2008(SR).

REFERENCES

[1] A.K. Bhattacharya, G.Thiagarajan, *Chem. Rev.*, **1981**, 81,415.

- [2] (a) A. Michaelies, R.Kaehene, *Chem.Ber.*, 1891, 31, 1408.
 (b) A.E. Arbuzov, *J.Russ.Phys.Chem.Soc.*, 1906, 38, 68.
- [3] J.A Skijors, E.W.Logusch, Aliphatic Carbon –phosphorus Compounds as Herbicides, In Handbook of Organophosphorus Chemistry; R.Engel, Ed.; Marcel Dekker: New York, **1992**, 739.

[4] B.Kaboudin, M.S. Bala Krishna, Synth.Commun. 2001, 31, 2773.

[5] T.M. Balthazor, R.C. Grabiak, J.Org.Chem, 1980, 45, 5425.

[6] V.K.Yadav, Synth. Commun. 1990, 20, 239.

[7] K. Toshima, H.Yamagushi, T. Jyojima, Y.Nogushi, M.Nakata, S. Matsumura, *Tetrahedron* Lett. **1996**, 37, 1073

[8] W. Flish, P. Rubkamp, W.Langer, Liebigs, Ann. Chem. 1985, 1413.

[9] D.Shukla, C.Lu, N.P. Schepp, W.G. Bentrude, L.J. Johnston, J.Org. Chem. 2000, 65, 6167.

[10] P.Y. Renard, P. Vayron, E. Leclerc, A.Valleix, C. Mioskowski, Angew. Chem. Int.Ed. 2003, 42, 2389.

[11] Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Sixteen International Supplements. CLSI document M100 S16. vol. 26-3; M7–A7, vol. 26-2; M2-A9, vol. 26-1. Wayne, PA, USA, **2006**.

[12] T.P.M. Akarboom, H. Sies, Assay of Glutathione, Glutathione Disulfide and Glutathione mixed Disulfides in Biological Samples. In: W.B. Jakoby (Ed.), Methods in Enzymology, vol. 77. Academic Press, New York, **1981**, 373–382.

[13] G. Syam Prasad, M. Manjunath Reddy, K. Kishore Kumar Reddy, O.Vijaya Sarathi Reddy, C. Suresh Reddy. *Arkivoc* 2006, *xvi*, 128.

[14] 14. W.L.F. Armarego, D.D. Perrin, Purification of Laboratory Chemicals, forth ed. Butterworth, Heinemann, Oxford, OX2 8DP **1997.**